Viracta Therapeutics Stock Performance
| VIRX Stock | USD 0.15 0.01 6.25% |
The entity has a beta of -1.6, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Viracta Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Viracta Therapeutics is expected to outperform it. At this point, Viracta Therapeutics has a negative expected return of -0.86%. Please make sure to validate Viracta Therapeutics' maximum drawdown and rate of daily change , to decide if Viracta Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 285:1000 | Dividend Date 2020-09-03 | Last Split Date 2021-02-25 |
1 | Viracta Therapeutics SWOT analysis narrowed focus shapes stock outlook - Investing.com | 09/30/2024 |
2 | Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positi... | 11/06/2024 |
3 | Contrasting ALX Oncology Viracta Therapeutics | 11/19/2024 |
| Begin Period Cash Flow | 36.8 M |
Viracta |
Viracta Therapeutics Relative Risk vs. Return Landscape
If you would invest 28.00 in Viracta Therapeutics on August 23, 2024 and sell it today you would lose (13.00) from holding Viracta Therapeutics or give up 46.43% of portfolio value over 90 days. Viracta Therapeutics is currently does not generate positive expected returns and assumes 4.5861% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Viracta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viracta Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viracta Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viracta Therapeutics, and traders can use it to determine the average amount a Viracta Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1886
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIRX |
Estimated Market Risk
| 4.59 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.86 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viracta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viracta Therapeutics by adding Viracta Therapeutics to a well-diversified portfolio.
Viracta Therapeutics Fundamentals Growth
Viracta Stock prices reflect investors' perceptions of the future prospects and financial health of Viracta Therapeutics, and Viracta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viracta Stock performance.
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 1.82 M | ||||
| Shares Outstanding | 39.74 M | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) | ||||
| Net Income | (51.06 M) | ||||
| Cash And Equivalents | 83.14 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 25.56 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (39.89 M) | ||||
| Earnings Per Share | (1.10) X | ||||
| Market Capitalization | 6.04 M | ||||
| Total Asset | 56.69 M | ||||
| Retained Earnings | (265.93 M) | ||||
| Working Capital | 16.59 M | ||||
About Viracta Therapeutics Performance
Evaluating Viracta Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Viracta Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Viracta Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.4 K | -1.5 K | |
| Return On Tangible Assets | (0.90) | (0.95) | |
| Return On Capital Employed | (2.77) | (2.91) | |
| Return On Assets | (0.90) | (0.95) | |
| Return On Equity | (2.79) | (2.93) |
Things to note about Viracta Therapeutics performance evaluation
Checking the ongoing alerts about Viracta Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viracta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viracta Therapeutics generated a negative expected return over the last 90 days | |
| Viracta Therapeutics has some characteristics of a very speculative penny stock | |
| Viracta Therapeutics has high historical volatility and very poor performance | |
| Viracta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Viracta Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Contrasting ALX Oncology Viracta Therapeutics |
- Analyzing Viracta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viracta Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viracta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viracta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viracta Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viracta Therapeutics' stock. These opinions can provide insight into Viracta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.